Working… Menu

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03272334
Recruitment Status : Recruiting
First Posted : September 5, 2017
Last Update Posted : May 8, 2020
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Patrick Dillon, MD, University of Virginia